Silverback Therapeutics Receivables

The latest receivables for SBTX is $29M as of March 2026. That compares with $9.3M in the prior-year period — up 208.1% year over year. Investors often review this figure alongside Silverback Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SBTX's receivables moved from $9.3M to $29M — a 208.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Silverback Therapeutics's operating scale or balance-sheet position.

A receivables figure of $29M for SBTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SBTX's receivables ($29M), review year-over-year change from $9.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Silverback Therapeutics's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.